TWP
RVMD icon

TFO Wealth Partners’s Revolution Medicines RVMD Stock Holding History

TFO Wealth Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7
Closed -$187 – 1061
2023
Q3 		$187 Buy
+7
New +$208 ﹤0.01% 832

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

TFO Wealth Partners's RVMD Position: Q4 2023 in Review

TFO Wealth Partners sold out of Revolution Medicines (RVMD) in Q4 2023, closing a stake of 7 shares — an estimated $187 sold.

TFO Wealth Partners first reported a position in RVMD in Q3 2023 and held it in 1 quarter. The position peaked at $187 in Q3 2023. 184 funds tracked by Wall St. Rank hold RVMD as of Q4 2023.

  • TFO Wealth Partners reported no remaining Revolution Medicines position as of Q4 2023 after selling out during the quarter.
  • TFO Wealth Partners sold 7 Revolution Medicines shares in Q4 2023, an estimated $187.
  • TFO Wealth Partners first reported a position in Revolution Medicines in Q3 2023 and held it in 1 quarter.
  • TFO Wealth Partners's Revolution Medicines position peaked at $187 in Q3 2023.
  • 184 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2023.

Based on TFO Wealth Partners's 13F filing for Q4 2023, filed 12 Feb 2024.